Trastuzumab Recruiting Phase 1 / 2 Trials for Breast Cancer Treatment

Indications	Status	Purpose	Phase
DBCOND0028036 (Breast Cancer)	Recruiting	Treatment	1 / 2

clinicaltrials.gov Identifier	Title	Drugs
NCT01969643	A Safety Study of SGN-LIV1A in Breast Cancer Patients	Ladiratuzumab vedotin (DB15409) Trastuzumab (DB00072)
NCT03716180	DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC	Trastuzumab (DB00072) Pertuzumab (DB06366) Paclitaxel (DB01229)
NCT03135171	Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab	Pertuzumab (DB06366) Trastuzumab (DB00072) Tocilizumab (DB06273)